Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
← catalyst calendarNCT05607420 · readout ≤ 377 d
Sponsored by Cellectis S.A. (industry) · CLLS — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
80estimated
Sites
10
Countries
France, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-01 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
- Biological: UCART20x22
- Biological: CLLS52 — also filed as Alemtuzumab
Primary outcomes
what the primary-completion date above is the date OFDose finding and expansion parts: Incidence of adverse events/serious adverse events/dose limiting toxicity [Safety and Tolerability]
measured From study entry through month 12
Dose finding part: Occurrence of Dose Limiting Toxicities (DLTs)
measured Up to Day 28 post UCART20x22 infusion
Permalink · CLLS's whole pipeline · Catalyst calendar · Every registered study · What changed